Hyperkalemia: Comprehensive Clinical Overview

Definition and Classification

Hyperkalemia is defined as a serum potassium concentration greater than 5.0-5.5 mEq/L (mmol/L), representing a potentially life-threatening electrolyte abnormality that requires immediate recognition and treatment. 1

Classification by Severity

The European Society of Cardiology provides the most widely accepted classification system 2:

Mild hyperkalemia: 5.0-5.9 mEq/L
Moderate hyperkalemia: 6.0-6.4 mEq/L
Severe hyperkalemia: ≥6.5 mEq/L

Critical caveat: ECG changes (peaked T waves, flattened P waves, prolonged PR interval, widened QRS) indicate urgent treatment regardless of the absolute potassium level, as these findings signal imminent cardiac toxicity 2. However, ECG findings are highly variable and less sensitive than laboratory tests, so their absence does not exclude dangerous hyperkalemia 2.

Pathophysiology

Fundamental Mechanisms

Hyperkalemia develops through three primary pathophysiologic mechanisms 3:

Impaired renal potassium excretion (dominant cause in clinical practice)
Transcellular shift of potassium from intracellular to extracellular space
Excessive potassium intake in the setting of impaired renal function

Renal Excretion Failure

The kidneys are the primary regulators of potassium homeostasis, and impaired renal excretion is the dominant cause of sustained hyperkalemia. 2 The incidence increases dramatically with severity of renal impairment, occurring in up to 73% of patients with advanced chronic kidney disease 3. Risk progressively increases as eGFR decreases, particularly when eGFR falls below 60 mL/min per 1.73 m² in patients on RAAS inhibitors 3.

Transcellular Shifts

Several conditions cause potassium to shift out of cells 3:

Metabolic acidosis: Hydrogen ions enter cells in exchange for potassium ions
Insulin deficiency: Impairs cellular potassium uptake via Na/K-ATPase 3
Beta-blocker therapy: Impairs cellular potassium uptake 3
Massive tissue breakdown: Rhabdomyolysis, tumor lysis syndrome, severe burns release large amounts of intracellular potassium 3

Cardiac Effects

Hyperkalemia has depolarizing effects on the heart, causing shortened action potentials and increasing the risk of fatal arrhythmias. 2 A U-shaped curve exists between serum potassium and mortality, with both hyperkalemia and hypokalemia associated with adverse outcomes 2.

Causes and Risk Factors

Drug-Induced Hyperkalemia (Most Important Iatrogenic Cause)

Medications represent the most important iatrogenic cause of hyperkalemia in everyday clinical practice, with up to 40% of heart failure patients and 5-10% of combination therapy patients developing hyperkalemia. 3

RAAS Inhibitors (Primary Culprits)

ACE inhibitors, ARBs, direct renin inhibitors 4
Mineralocorticoid receptor antagonists (spironolactone, eplerenone) 4
Critical warning: The triple combination of ACE inhibitor + ARB + MRA is NOT recommended due to excessive hyperkalemia risk 2

Other High-Risk Medications

NSAIDs: Impair renal potassium excretion by reducing prostaglandin synthesis 3, 4
Potassium-sparing diuretics: Amiloride, triamterene 3, 4
Trimethoprim and pentamidine: Block epithelial sodium channels in the collecting duct 3, 4
Heparin and derivatives: Suppress aldosterone synthesis 3, 4
Beta-blockers: Impair cellular potassium uptake 3
Calcineurin inhibitors (tacrolimus, cyclosporine) 4

High-Risk Comorbidities

Patients with the following conditions have dramatically elevated risk 3:

Chronic kidney disease (especially eGFR <60 mL/min per 1.73 m²)
Heart failure
Diabetes mellitus (through hyporeninemic hypoaldosteronism and insulin deficiency) 3
Advanced age (altered potassium homeostasis) 3
Acute kidney injury (often accompanied by acute pancreatitis or hepatic failure) 3

Excessive Potassium Intake

Potassium supplements (direct exogenous source) 3
Salt substitutes containing potassium chloride 3
High-potassium foods: Bananas, melons, orange juice, potatoes, tomatoes 3
Important note: Evidence linking dietary potassium intake to serum levels is limited, and potassium-rich diets provide cardiovascular benefits including blood pressure reduction 2

Pseudohyperkalemia (Critical to Exclude)

Pseudohyperkalemia represents falsely elevated potassium in the test tube without true elevation in the body. 3 Causes include:

Hemolysis during blood draw 3
Prolonged tourniquet application or repeated fist clenching 3
Thrombocytosis or leukocytosis 3
Delayed specimen processing 3

If pseudohyperkalemia is suspected, repeat measurement with proper blood sampling technique or obtain an arterial sample for confirmation. 3

Signs and Symptoms

Clinical Presentation

Symptoms of hyperkalemia are typically nonspecific and predominantly related to muscular or cardiac dysfunction, making ECG and laboratory confirmation essential. 2, 5

Neuromuscular Manifestations

Muscle weakness or paralysis 5
Paresthesias 5
Ascending paralysis (in severe cases) 5

Cardiac Manifestations (Most Dangerous)

ECG changes are the most critical clinical findings and indicate urgent treatment need 2:

Progressive ECG changes with increasing potassium levels:

Peaked T waves (earliest finding)
Flattened P waves
Prolonged PR interval
Widened QRS complexes
Sine wave pattern (pre-arrest rhythm)
Ventricular fibrillation or asystole

Critical pitfall: Do not rely solely on ECG findings—they are highly variable and less sensitive than laboratory tests 2. However, their presence mandates immediate treatment regardless of the potassium level 2.

Rate of Rise Matters

Both the absolute potassium level and the rate of rise determine clinical significance, with rapid increases more likely to cause cardiac abnormalities than gradual elevations over months. 3 The faster the rise occurs, the faster life-threatening symptoms develop 6.

Management

Initial Assessment Algorithm

Before initiating treatment, verify the result is not pseudohyperkalemia from hemolysis, repeated fist clenching, or poor phlebotomy technique. 2

Obtain ECG immediately to assess for cardiac toxicity 2
Verify potassium level with proper blood sampling technique 2
Assess severity based on potassium level AND ECG changes 2
Identify underlying cause and contributing medications 2

Acute Hyperkalemia Management (Emergency Treatment)

For severe hyperkalemia (≥6.5 mEq/L) or any ECG changes, treatment should be initiated immediately with a three-pronged approach: cardiac membrane stabilization, intracellular potassium shift, and potassium removal from the body. 2

Step 1: Cardiac Membrane Stabilization (First Priority)

Administer intravenous calcium FIRST to protect against arrhythmias within 1-3 minutes. 2

Calcium gluconate (10%): 15-30 mL IV over 2-5 minutes 2
OR Calcium chloride (10%): 5-10 mL IV over 2-5 minutes 2

Critical points:

Effects begin within 1-3 minutes but are temporary (30-60 minutes) 2
Calcium does NOT lower potassium—it only stabilizes cardiac membranes temporarily 2
If no ECG improvement within 5-10 minutes, repeat the dose 2
Continuous cardiac monitoring is mandatory during and after administration 2
Never administer calcium through the same IV line as sodium bicarbonate—precipitation will occur 2

Special consideration: In patients with malignant hyperthermia and hyperkalemia, calcium should only be used in extremis as it may contribute to calcium overload 2

Step 2: Shift Potassium Into Cells (Temporizing Measures)

Give all three agents together for maximum effect 2:

Insulin + Glucose (Most Effective Shift Agent)

Standard dose: 10 units regular insulin IV + 25g dextrose (50 mL of D50W) 2
Onset: 15-30 minutes 2
Duration: 4-6 hours 2
Can be repeated every 4-6 hours if hyperkalemia persists 2
Critical warning: Always give glucose with insulin to prevent hypoglycemia 2
Monitor glucose and potassium every 2-4 hours after administration 2
High-risk patients for hypoglycemia: Low baseline glucose, no diabetes, female sex, altered renal function 2

Nebulized Beta-2 Agonist (Adjunctive Therapy)

Albuterol 10-20 mg in 4 mL nebulized 2
Onset: 15-30 minutes 2
Duration: 2-4 hours 2
Works synergistically with insulin 2

Sodium Bicarbonate (ONLY if Metabolic Acidosis Present)

Dose: 50 mEq IV over 5 minutes 2
Indication: ONLY use in patients with concurrent metabolic acidosis (pH <7.35, bicarbonate <22 mEq/L) 2
Onset: 30-60 minutes 2
Mechanism: Promotes potassium excretion through increased distal sodium delivery and counters acidosis-induced potassium release 2
Critical pitfall: Do not use sodium bicarbonate without metabolic acidosis—it is ineffective and wastes time 2

Step 3: Remove Potassium From Body (Definitive Treatment)

Remember that calcium, insulin, and beta-agonists do NOT remove potassium from the body—they only temporize. 2

Loop Diuretics (If Adequate Renal Function)

Furosemide 40-80 mg IV 2
Increases renal potassium excretion by stimulating flow to renal collecting ducts 2
Should be titrated to maintain euvolemia, not primarily for potassium management 2

Hemodialysis (Most Effective and Reliable Method)

Indications: Severe hyperkalemia unresponsive to medical management, oliguria, or end-stage renal disease 2
Most effective method for potassium removal 2
Monitor for rebound hyperkalemia within 4-6 hours post-dialysis as intracellular potassium redistributes 2

Potassium Binders (For Acute and Chronic Management)

Sodium zirconium cyclosilicate (SZC/Lokelma) - Preferred for acute scenarios:

Acute dosing: 10 g three times daily for 48 hours 2
Maintenance: 5-15 g once daily 2
Onset: ~1 hour (fastest acting) 2
Reduces serum potassium within 1 hour of a single 10-g dose 2

Patiromer (Veltassa) - Preferred for chronic management:

Starting dose: 8.4 g once daily with food 2
Titration: Up to 25.2 g daily based on potassium levels 2
Onset: ~7 hours 2
Critical administration requirement: Separate from other oral medications by at least 3 hours 2
Monitor magnesium levels (can cause hypomagnesemia) 2

Sodium polystyrene sulfonate (Kayexalate) - AVOID

The European Heart Journal recommends avoiding sodium polystyrene sulfonate for acute management due to delayed onset, limited efficacy, and risk of bowel necrosis. 2
Associated with intestinal ischemia, colonic necrosis, and doubling of risk for serious gastrointestinal adverse events 2

Medication Management During Acute Episode

Temporarily discontinue or reduce RAAS inhibitors at K+ ≥6.5 mEq/L. 2 Also review and hold:

NSAIDs 2
Potassium-sparing diuretics 2
Trimethoprim 2
Heparin 2
Beta-blockers 2
Potassium supplements 2
Salt substitutes 2

Chronic Hyperkalemia Management

The most critical principle: Do NOT permanently discontinue RAAS inhibitors in patients with cardiovascular disease, heart failure, or proteinuric CKD—these medications provide mortality benefit and slow disease progression. 2 Instead, use potassium binders to enable continuation of life-saving medications 2.

Treatment Algorithm Based on Potassium Level

For patients on RAAS inhibitors with K+ 5.0-6.5 mEq/L:

Initiate patiromer or SZC while maintaining RAAS inhibitor therapy 2
Do NOT discontinue RAAS inhibitors unless alternative treatable cause identified 2

For patients on RAAS inhibitors with K+ >6.5 mEq/L:

Temporarily discontinue or reduce RAAS inhibitor 2
Initiate potassium binder 2
Restart RAAS inhibitor at lower dose once K+ <5.5 mEq/L with concurrent potassium binder therapy 2

Medication Optimization Strategy

Review and eliminate contributing medications:

NSAIDs (attenuate diuretic effects and impair renal potassium excretion) 2
Trimethoprim 2
Heparin 2
Beta-blockers 2
Potassium supplements 2
Salt substitutes 2

Optimize diuretic therapy:

Loop or thiazide diuretics promote urinary potassium excretion 2
Furosemide 40-80 mg daily if adequate renal function present 2

Consider fludrocortisone (use cautiously):

Increases potassium excretion but carries risks of fluid retention, hypertension, and vascular injury 2
Should be used only when other options are exhausted 2

Potassium Binder Selection for Chronic Management

Patiromer (Veltassa) - First-line for chronic management:

Starting dose: 8.4 g once daily with food 2
Titration: Can increase to 16.8 g or 25.2 g daily based on response 2
Mechanism: Exchanges calcium for potassium in the colon 2
Administration: Separate from other medications by at least 3 hours 2
Monitoring: Check magnesium levels (can cause hypomagnesemia and hypercalcemia) 2
Evidence: Enables 86% of patients to remain on spironolactone 50 mg daily versus 66% with placebo 2

Sodium zirconium cyclosilicate (SZC/Lokelma) - Alternative first-line:

Starting dose: 10 g three times daily for 48 hours, then 5-15 g once daily 2
Mechanism: Highly selective potassium binding, exchanges hydrogen and sodium for potassium 2
Onset: ~1 hour 2
Additional benefit: May improve metabolic acidosis by increasing ammonium excretion 2
Monitoring: Watch for edema due to sodium content 2

Monitoring Protocol

Check potassium within 1 week of starting or escalating RAAS inhibitors. 2

Reassess 7-10 days after initiating potassium binder therapy. 2

Individualize monitoring frequency based on:

eGFR (more frequent if <60 mL/min per 1.73 m²) 2
Heart failure 2
Diabetes 2
History of hyperkalemia 2

For high-risk patients: Check potassium and renal function at 1-2 weeks, 3 months, then every 6 months 2

Critical monitoring caveat: Monitor closely not only for efficacy but also to protect against hypokalemia, which may be even more dangerous than hyperkalemia 2

Special Population: Advanced CKD

Patients with advanced CKD tolerate higher potassium levels due to compensatory mechanisms. 2

Optimal potassium ranges:

Stage 1-2 CKD: 3.5-5.0 mEq/L 2
Stage 4-5 CKD: 3.3-5.5 mEq/L 2
Target for all CKD stages: 4.0-5.0 mEq/L minimizes mortality risk 2

Maintain RAAS inhibitors aggressively in proteinuric CKD using potassium binders, as these drugs slow CKD progression. 2

Dietary Considerations

Evidence linking dietary potassium intake to serum potassium is limited, and potassium-rich diets provide cardiovascular benefits including blood pressure reduction. 2

Newer potassium binders may allow for less restrictive dietary potassium restrictions, enabling patients to benefit from potassium-rich foods. 2

However, eliminate:

High-potassium salt substitutes 2
Herbal supplements (alfalfa, dandelion, horsetail, nettle) 2

Team Approach to Management

Optimal chronic hyperkalemia management involves a multidisciplinary team: 2

Cardiologists
Nephrologists
Primary care physicians
Nurses
Pharmacists
Social workers
Dietitians

Critical Pitfalls to Avoid

Never delay treatment while waiting for repeat lab confirmation if ECG changes are present—ECG changes indicate urgent need regardless of the exact potassium value. 2

Never use sodium bicarbonate without metabolic acidosis—it is ineffective and wastes time. 2

Never give insulin without glucose—hypoglycemia can be life-threatening. 2

Never rely solely on ECG findings—they are highly variable and less sensitive than laboratory tests. 2

Remember that calcium, insulin, and beta-agonists do NOT remove potassium from the body—they only temporize. 2 Failure to initiate concurrent potassium-lowering therapies will result in recurrent life-threatening arrhythmias within 30-60 minutes 2.

Do not permanently discontinue RAAS inhibitors in patients with cardiovascular disease or proteinuric CKD—use potassium binders instead to maintain these life-saving medications. 2

What is hyperkalemia, including its definition, classification, causes, pathophysiology, signs and symptoms, and management?

Help us tailor your experience